NYB.AI and Pnaseer Inc. Announce Strategic Partnership to Advance AI-Powered Hair Regeneration Research

Singapore - July 3rd 2025 - NYB.AI and Pnaseer Inc. have announced a strategic partnership focused on accelerating innovation in hair follicle regeneration through the integration of artificial intelligence and targeted drug delivery technologies. This collaboration combines NYB.AI’s proprietary AI platform for compound-target interaction prediction with Pnaseer’s advanced bio-nanoparticle delivery system to enable the efficient development of therapeutic compounds for regenerative medicine.

‍

The partnership brings together complementary strengths from both organizations. NYB.AI contributes a robust computational platform capable of modeling and predicting molecular interactions across complex biological networks. Pnaseer enhances this capability with its proprietary delivery technology, designed to improve therapeutic precision, increase bioavailability, and target specific tissues more effectively.

‍

At the core of this collaboration is Project Follica - a joint initiative that aims to discover and develop a new generation of compounds that can stimulate hair follicle regeneration with higher efficacy and safety. The project focuses on both natural and synthetic molecules, selected through advanced in silico screening and validated through in vitro assays. NYB.AI’s platform will prioritize candidates with strong biological relevance, while Pnaseer will design delivery systems that ensure optimal therapeutic performance.

‍

This collaboration reflects a shared commitment between NYB.AI and Pnaseer to push the boundaries of biotech innovation. By combining deep learning models, biological data, and formulation science, the two companies aim to build a scalable, data-driven framework for faster, more effective therapeutic development.

‍

About NYB.AI

NYB.AI is a biotech company using AI and biological data to understand drug-target interactions in disease pathways. Through its AI platform and compound libraries, NYB.AI identifies promising therapeutic molecules and optimizes them for effectiveness. Using advanced machine learning techniques, NYB.AI accelerates the discovery of next-generation treatments for cancer and chronic diseases.

‍

–  

‍

About Pnaseer Inc:

Pnaseer Inc. (Pnaseer) is a biotechnology company specializing in the development of advanced drug delivery technologies. Pnaseer is dedicated to enhancing the therapeutic performance of approved drugs through the application of its proprietary bio-nanoparticle platform. By enabling more precise and efficient delivery of active compounds, Pnaseer's technology supports a broad range of applications, from pharmaceutical formulation/manufacturing to wellness-focused treatments, with PNAS Therapeutics focusing on clinical development and commercialization.

‍